Oncology

Merck and Moderna’s adjuvant melanoma treatment shows reduced risk of recurrence or death by 44% compared with pembrolizumab alone.

E7777 is an engineered interleukin-2-diphtheria toxin fusion protein that is a purified and more bioactive formulation of Ontak, which the agency previously approved.

Ponatinib could be the first targeted treatment approved in the United States for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Following the positive phase 3 results, GSK anticipates regulatory submissions in the first half of 2023.

Despite a limited understanding about access to oral anticancer drugs, new research finds challenges in patient and clinician decision-making.

Expert discusses the patient-reported outcomes from the GRIFFIN trial at the final study analysis after all patients completed 1 year of follow-up post maintenance therapy.

Expert discusses updated cohort of patients with longer-term follow up treated in the phase 2 clinical trial of venetoclax added to cladribine plus low-dose araC alternating with azacytidine.

Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

Phase 1 clinical trial data show the drug to be active with evidence of clinically meaningful responses and a manageable safety profile.

Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.

Regular physical activity helps to facilitate a healthy gut microbiome and lowers inflammation, which were observed in patients independent of body mass index.

Long-term data showed no difference in the clinical benefit between the treatments for HER2-negative early breast cancer with homologous recombination deficiency.

Study findings may make durvalumab plus chemotherapy a new standard of care option for patients with advanced biliary tract cancer.

Expert discusses clinical outcomes of the phase 3 ZUMA-7 trial assessing axicabtagene ciloleucel versus standard-of-care in second-line large B-cell lymphoma by metabolic tumor volume.

At 3 and 6 months, rivaroxaban was found to be as effective and safe as apixaban in the composite outcome of recurrent venous thromboembolism or bleeding-related hospitalization.

The phase 3 clinical trial shows that the 5-year OS for patients with HR+/HER2- advanced breast cancer in the abemaciclib plus fulvestrant group was 41.2% vs 29.2% for the placebo arm.

Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.

BYLieve clinical trial data indicate long-term and very-long-term data disease control was observed in 25.6% and 16.5% of patients, respectively, with PFS at 24.8 and 29.4 months in patients with HR-positive, HER2-negative advanced breast cancer.

The presence of CD8+ cells may help predict outcomes for patients administered immune checkpoint inhibitors.

Efficacy and safety profile in combination with alpelisib is comparable to that reported in the BYLieve and SOLAR-1 clinical trials, according to a poster presentation at the San Antonio Breast Cancer Symposium.

Pharmacy Times will be covering the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which gathers pharmacy professionals working in malignant and classical hematology in New Orleans, Louisiana.

Dawn L. Hershman, MD, MS, Columbia University Medical Center, New York, NY, presents her findings at the 2022 San Antonio Breast Cancer Symposium.

Clinical trial results found that second-line treatment with trastuzumab deruxtecan led to significantly longer overall survival compared with trastuzumab emtansine.

DESTINY-Breast02 clinical trial results show trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in progression-free and overall survival.

Study finds textured breast implants do not increase the risk of anaplastic large-cell lymphoma, which has grown in incidence since 2008.

Tumor microenvironment differences in Black women may explain disparities in outcomes for those with residual tumors after chemotherapy treatment for ER–positive/HER2-negative breast cancer.

Breast cancer expert joined a panel to discuss aromatase inhibitors at the San Antonio Breast Cancer Symposium (SABCS) on December 6, 2022.